Provided by Tiger Trade Technology Pte. Ltd.

Kiora Pharmaceuticals

2.56
-0.0200-0.78%
Post-market: 2.560.00000.00%16:10 EDT
Volume:3K
Turnover:9K
Market Cap:11.35M
PE:-1.06
High:2.56
Open:2.55
Low:2.55
Close:2.58
52wk High:2.95
52wk Low:1.76
Shares:4.43M
Float Shares:4.29M
Volume Ratio:0.49
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4100
EPS(LYR):-2.6400
ROE:-56.36%
ROA:-21.92%
PB:0.67
PE(LYR):-0.97

Loading ...

Nov 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 08, 2024

Major Issues Report

Form 8-K - Current report
Oct 29, 2024

Major Issues Report

Form 8-K - Current report
Aug 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 09, 2024

Major Issues Report

Form 8-K - Current report
Jul 30, 2024

Major Issues Report

Form 8-K - Current report
Jul 01, 2024

Major Issues Report

Form 8-K - Current report
Jun 07, 2024

Major Issues Report

Form 8-K - Current report
May 29, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 29, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 10, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 10, 2024

Major Issues Report

Form 8-K - Current report
May 10, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
May 03, 2024

Major Issues Report

Form 8-K - Current report
Mar 27, 2024

Correspondence

Form CORRESP - Correspondence
Mar 25, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 25, 2024

Major Issues Report

Form 8-K - Current report
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 12, 2024

Major Issues Report

Form 8-K - Current report